Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Country Outlook | Forecast 2023-2030
Triton’s research report predicts that the ophthalmic drugs market in North America will achieve revenue at 6.09% CAGR in the forecast years 2023-2030.
Report scope can be customized per your requirements - Request Free Sample Report
The countries analyzed in the studied region include:
•        United
States
•        Canada
Demographic
trends, lifestyle changes, and aging-related eye disorders together drive the
need for ophthalmic drugs. The landscape of ophthalmic care is evolving with a
shift in advanced diagnostic technologies, genetic testing, precision medicine, and personalized treatments for
patients. In
spite of high costs, stringent regulatory requirements, and approval process by
the FDA, the North
American ophthalmic drugs market reflects a positive
growth.
The United
States leads with a major share
in the region’s ophthalmic
drugs market. As more and more demographic portion enters an
older age bracket, conditions like diabetic retinopathy, macular degeneration,
and glaucoma are rising. Similarly, lifestyle changes with prolonged screen
exposure also result in conditions like dry eye syndrome among the younger
population. These two factors positively induce the demand for ophthalmic
pharmaceuticals.
Canada also witnessed a pivotal shift in pharmaceutical innovations. The presence of a robust healthcare system provides a strong network of eye care treatments and adopts a proactive approach to curing eye disorders. However, the challenges faced in this industry are the approval of regulatory processes, higher costs of drug development, and inaccessibility of eye care in remote areas. Resolving these issues can improve the overall functioning of eye care services, thereby creating a scope to expand the use of ophthalmic drugs.Â
Anti-glaucoma
medications are used to treat a group of eye-related diseases that cause optic
nerve damage. These drugs help lower the intraocular pressure inside the eyes
and avoid the risk of irreversible loss of vision. The first line of treatment
often includes a daily dose of anti-glaucoma drugs, which often includes eye drops. The market segments for ophthalmic drugs are determined based on type, delivery method, therapeutic
type, condition, and channel. The therapeutic type segment consists of anti-glaucoma, anti-infection, anti-inflammatory,
anti-allergy, and other therapeutic classes.
The leading market players in the ophthalmic
drugs market
are AbbVie
Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Pfizer
Inc, Sun Pharmaceutical Industries Ltd, Johnson & Johnson, Thea Pharma Inc, Novartis AG, Accutome Inc, and Genentech
Inc.
AbbVie
Inc specializes in biopharmaceuticals that discover, manufacture, develop, and
commercialize drugs for treating chronic and complex diseases, neurological
disorders, viral diseases, skin diseases, metabolic diseases, rheumatological
diseases, etc. The company markets its products directly to healthcare
facilities, specialty pharmacies, government agencies, wholesalers,
distributors, and independent retailers worldwide. The headquarters is situated
in North Chicago, Illinois, United States.
KEY
DELIVERABLES OF THE REPORT:
â—ŹÂ Â Â Â Â
Market CAGR during the forecasting years 2023-2030
â—ŹÂ Â Â Â Â
Detailed data highlighting key insights, industry components, and
market strategies
â—ŹÂ Â Â Â Â
Comprehensive information and estimation of the ophthalmic
drugs
market revenue growth in North America and its influence on the parent market
â—ŹÂ Â Â Â Â
In-depth study of forthcoming trends in consumer behavioral
patterns
â—ŹÂ Â Â Â Â
A meticulous analysis of the competitive landscape, vendor
scorecard, and Porter’s Five Forces
â—ŹÂ Â Â Â Â
A wide-ranging study of factors that will challenge the North
American ophthalmic drugs market’s growth during the upcoming
years
Want to get specific insights? Our team of
analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. NORTH
AMERICA OPHTHALMIC DRUGS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TECHNOLOGY
SNAPSHOT
2.2. IMPACT
ANALYSIS ON THE OPHTHALMIC DRUGS MARKET
2.2.1. COVID-19
IMPACT ON THE OPHTHALMIC DRUGS MARKET
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
MATURITY ANALYSIS
2.5. REGULATORY
FRAMEWORK
2.6. KEY
BUYING IMPACT ANALYSIS
2.7. KEY
MARKET STRATEGIES
2.7.1. COLLABORATIONS
2.7.2. PRODUCT
LAUNCHES
2.7.3. MERGERS
& ACQUISITIONS
2.8. MARKET
DRIVERS
2.8.1. AGING
2.8.2. PROGRESS
IN DRUG DELIVERY TECHNOLOGIES
2.8.3. ESCALATING
INCIDENCE OF OCULAR DISEASES
2.8.4. REIMBURSEMENT
POLICIES BY HEALTHCARE SYSTEMS
2.9. MARKET
CHALLENGES
2.9.1. CHALLENGING
TIMELINES FOR PRODUCT APPROVAL
2.9.2. ADVERSE
EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE
2.10. MARKET
OPPORTUNITIES
2.10.1. SURGE
IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS
2.10.2. INCREASE
IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES
2.11. ANALYST
PERSPECTIVE
3. NORTH
AMERICA OPHTHALMIC DRUGS MARKET – BY TYPE
3.1. PRESCRIPTION
DRUGS
3.2. OVER-THE-COUNTER
DRUGS
4. NORTH
AMERICA OPHTHALMIC DRUGS MARKET – BY CONDITION
4.1. DRY
EYE
4.2. GLAUCOMA
4.3. INFECTION/INFLAMMATION/ALLERGIES
4.4. RETINAL
DISORDER
4.4.1. WET-AGE
RELATED MACULAR DEGENERATION
4.4.2. DRY-AGE
RELATED MACULAR DEGENERATION
4.4.3. DIABETIC
RETINOPATHY
4.4.4. OTHER
RETINAL DISORDERS
4.5. OTHER
CONDITIONS
5. NORTH
AMERICA OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE
5.1. ANTI-GLAUCOMA
5.2. ANTI-INFECTION
5.3. ANTI-INFLAMMATORY
5.4. ANTI-ALLERGY
5.5. OTHER
THERAPEUTIC TYPES
6. NORTH
AMERICA OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD
6.1. GELS
6.2. EYE
SOLUTIONS & SUSPENSIONS
6.3. CAPSULES
& TABLETS
6.4. EYE
DROPS
6.5. OINTMENTS
7. NORTH
AMERICA OPHTHALMIC DRUGS MARKET – BY CHANNEL
7.1. HOSPITAL
PHARMACIES
7.2. DRUG
STORES
7.3. ONLINE
PHARMACIES
7.4. OTHER
CHANNELS
8. NORTH
AMERICA OPHTHALMIC DRUGS MARKET – COUNTRY OUTLOOK
8.1. UNITED
STATES
8.1.1. UNITED
STATES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2. CANADA
8.2.1. CANADA
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
9. COMPETITIVE
LANDSCAPE
9.1. ABBVIE
INC
9.1.1. OVERVIEW
9.1.2. PRODUCT
PORTFOLIO
9.1.3. KEY
STRENGTHS
9.1.4. KEY
CHALLENGES
9.2. BAUSCH
HEALTH COMPANIES INC
9.2.1. OVERVIEW
9.2.2. PRODUCT
PORTFOLIO
9.2.3. KEY
STRENGTHS
9.2.4. KEY
CHALLENGES
9.3. JOHNSON
& JOHNSON
9.3.1. OVERVIEW
9.3.2. PRODUCT
PORTFOLIO
9.3.3. KEY STRENGTHS
9.3.4. KEY
CHALLENGES
9.4. NOVARTIS
AG
9.4.1. OVERVIEW
9.4.2. PRODUCT
PORTFOLIO
9.4.3. KEY
STRENGTHS
9.4.4. KEY
CHALLENGES
9.5. REGENERON
PHARMACEUTICALS INC
9.5.1. OVERVIEW
9.5.2. PRODUCT
PORTFOLIO
9.5.3. KEY
STRENGTHS
9.5.4. KEY
CHALLENGES
9.6. SUN
PHARMACEUTICAL INDUSTRIES LTD
9.6.1. OVERVIEW
9.6.2. PRODUCT
PORTFOLIO
9.6.3. KEY
STRENGTHS
9.6.4. KEY
CHALLENGES
9.7. ACCUTOME
INC
9.7.1. OVERVIEW
9.7.2. PRODUCT
PORTFOLIO
9.7.3. KEY
STRENGTHS
9.7.4. KEY
CHALLENGES
9.8. GENENTECH
INC
9.8.1. OVERVIEW
9.8.2. PRODUCT
PORTFOLIO
9.8.3. KEY
STRENGTHS
9.8.4. KEY
CHALLENGES
9.9. THEA
PHARMA INC
9.9.1. OVERVIEW
9.9.2. PRODUCT
PORTFOLIO
9.9.3. KEY
STRENGTHS
9.9.4. KEY
CHALLENGES
9.10. PFIZER
INC
9.10.1. OVERVIEW
9.10.2. PRODUCT
PORTFOLIO
9.10.3. KEY
STRENGTHS
9.10.4. KEY
CHALLENGES
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: NORTH AMERICA
OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY
FRAMEWORK
TABLE 3: LIST OF
COLLABORATIONS
TABLE 4: LIST OF
PRODUCT LAUNCHES
TABLE 5: LIST OF
MERGERS & ACQUISITIONS
TABLE 6: NORTH AMERICA
OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 7: NORTH AMERICA
OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: NORTH AMERICA
OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)
TABLE 9: NORTH AMERICA
OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)
TABLE 10: NORTH AMERICA
OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)
TABLE 11: NORTH AMERICA
OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)
TABLE 12: NORTH AMERICA
OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)
FIGURE 1: TECHNOLOGY SNAPSHOT
FIGURE 2: MARKET MATURITY ANALYSIS
FIGURE 3: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030
(IN %)
FIGURE 4: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS,
2023-2030 (IN $ MILLION)
FIGURE 5: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER
DRUGS, 2023-2030 (IN $ MILLION)
FIGURE 6: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 &
2030 (IN %)
FIGURE 7: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030
(IN $ MILLION)
FIGURE 8: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030
(IN $ MILLION)
FIGURE 9: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY
INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)
FIGURE 10: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2023-2030 (IN $ MILLION)
FIGURE 11: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2022 & 2030 (IN %)
FIGURE 12: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED
MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 13: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED
MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 14: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DIABETIC
RETINOPATHY, 2023-2030 (IN $ MILLION)
FIGURE 15: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL
DISORDERS, 2023-2030 (IN $ MILLION)
FIGURE 16: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS,
2023-2030 (IN $ MILLION)
FIGURE 17: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE,
2022 & 2030 (IN %)
FIGURE 18: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA,
2023-2030 (IN $ MILLION)
FIGURE 19: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION,
2023-2030 (IN $ MILLION)
FIGURE 20: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY,
2023-2030 (IN $ MILLION)
FIGURE 21: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY,
2023-2030 (IN $ MILLION)
FIGURE 22: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC
TYPES, 2023-2030 (IN $ MILLION)
FIGURE 23: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD,
2022 & 2030 (IN %)
FIGURE 24: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN
$ MILLION)
FIGURE 25: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS &
SUSPENSIONS, 2023-2030 (IN $ MILLION)
FIGURE 26: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CAPSULES &
TABLETS, 2023-2030 (IN $ MILLION)
FIGURE 27: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030
(IN $ MILLION)
FIGURE 28: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030
(IN $ MILLION)
FIGURE 29: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 &
2030 (IN %)
FIGURE 30: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 31: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRUG STORES,
2023-2030 (IN $ MILLION)
FIGURE 32: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 33: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS,
2023-2030 (IN $ MILLION)
FIGURE 34: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK,
2022 & 2030 (IN %)
FIGURE 35: UNITED STATES OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $
MILLION)
FIGURE 36: CANADA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)